Litigation Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Docket	1:19-cv-00078-RGA	Date Filed	2019-01-14
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,566,729; 7,635,707; 7,696,236; 7,767,225; 7,767,700; 7,816,383; 7,910,610; 7,988,994; 8,013,002; 8,084,475; 8,318,780; 8,383,150; 8,420,674; 8,592,462; 8,609,701; 8,648,098; 8,753,679; 8,754,109; 8,778,947
Link to Docket	External link to docket

Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-14	226	Order - -Memorandum and Order	single term in U.S. Patent Nos. 7,566,729 (“the ’729 patent”), 7,635,707 (“the ’707 patent”), and 8,592,462… construction for a single term in U.S. Patent Nos. 7,566,729, 7,635,707, and 8,592,462. Plaintiffs'…the ‘729 patent, claims 2, 8, and 10 of the ‘707 patent, and claims 18 and 23 of the ‘462 patent. (D.I. … “It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification	External link to document
2019-01-14	4		B2; 7,696,236 B2; 7,767,700 B2; 8,420,674 B2; 7,566,729 B1; 7,635,707 B1; 8,592,462 B2; 8,609,701 B2; … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,767,225 B2; …January 2019 1:19-cv-00078-RGA 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Genentech, Inc. v. Aurobindo Pharma Limited

Last updated: February 2, 2026

Case Number: 1:19-cv-00078-RGA
Jurisdiction: United States District Court, District of Delaware

---

Executive Summary

This case involves patent infringement claims initiated by Genentech, Inc. against Aurobindo Pharma Limited. Genentech alleges that Aurobindo's biosimilar product infringes on multiple patents related to Rituxan (rituximab). The litigation exemplifies typical biosimilar patent disputes post-Biologics Price Competition and Innovation Act (BPCIA). The case underscores critical issues around patent validity, infringement, and biosimilar pathway policies, shaping market access for biosimilar drugs.

---

Case Background and Timeline

Date	Event	Details
August 2, 2018	Filing of Complaint	Genentech alleges patent infringement by Aurobindo’s proposed biosimilar.
January 8, 2019	Aurobindo’s Response and Counterclaims	Challenges patent validity, asserts non-infringement, and procedural defenses.
February 2019	Preliminary Proceedings	Motions for judgment on patent validity and infringement filed by both parties.
October 2019	Summary Judgment Motions	Pending at this stage, with ongoing discovery.
April 2020	Court asked to resolve multiple patent issues	Focused on the scope of patents, obviousness, and infringement claims.
August 2020	Status Conference and updates on discovery	Delays due to COVID-19 pandemic, with scheduling adjustments.
June 2021	Ongoing dispositive motion filings	Patent validity and infringement heavily contested.

---

Legal Claims and Patent Overview

Patents Asserted

Genentech’s complaint centers on the following patents related to rituximab:

Patent Number	Title	Claims Focus	Filing Date	Expiry Date
US 8,603,652	Methods of treatment with rituximab	Treatment methods utilizing rituximab	2013-09-11	2033-09-11
US 8,952,138	Purified composition of rituximab	Composition of matter with monoclonal antibody properties	2010-09-24	2030-09-24
US 9,989,986	Biosimilar rituximab and methods thereof	Biosimilar manufacturing and application	2016-03-14	2036-03-14

Alleged Patent Infringement

Genentech claims Aurobindo’s biosimilar infringes these patents through:

• Manufacturing processes
• Product formulation
• Use in treating diseases such as non-Hodgkin’s lymphoma and rheumatoid arthritis

Defenses Raised by Aurobindo

• Patent invalidity based on obviousness and prior art references
• Non-infringement of certain claims
• Lack of patent enforceability due to procedural issues
• Biosimilar approval pathway under the BPCIA

---

Patent Validity and Infringement Issues

Patent Validity Challenges

Aurobindo has challenged the patents’ validity citing:

• Obviousness: References to prior art suggesting similar compositions and methods
• Lack of Enablement: Insufficient detail in patent disclosures
• Anticipation: Prior publications or products that disclose the claimed invention

Infringement Analysis

Genentech asserts infringement via:

• Aurobindo's biosimilar's structural similarity
• Use of identical manufacturing steps or formulations
• Expected clinical indications matching the patent claims

Aurobindo's defenses include:

• Non-infringement by design differences
• Invalidity of the patents on legal grounds

Key Technical and Legal Considerations

Aspect	Details
Patent Scope	Claims cover manufacturing, composition, and methods
Biosimilar Pathway	Regulatory pathway via 351(k) under the BPCIA
Patent Term Challenges	Potential for extension or contestation during litigation
Court’s Approach	Emphasizes claim construction, patent scope, and validity

---

Policy and Industry Implications

Issue	Impact
Biosimilar Patent Litigation	Set precedents for future biosimilar disputes
Patent Term Extensions and Challenges	Influence on patent strategy for biologics
BPCIA Regulatory Framework	Clarifies biosimilar approval and patent litigation pathway

Note: The litigation reflects the broader biosimilar patent landscape in the U.S., governed by the BPCIA, which aims to balance innovation incentives and market competition (see 42 U.S.C. § 262).

---

Comparison with Similar Cases

Case	Key Issue	Outcome / Status	Relevance
Amgen Inc. v. Sandoz Inc.	Patent validity & infringement	Initially stayed, settled later	Sets precedent for biosimilar patent disputes
AbbVie v. Sandoz	Patent validity and non-infringement	Summary judgment for patent validity	Clarifies scope of patent claims
Celltrion Healthcare v. Janssen	Patent validity & infringement	Pending, similar issues being litigated	Highlights ongoing biosimilar patent tensions

---

Legal and Strategic Takeaways

• Patent Strategy: Innovators must ensure comprehensive claims and sufficient disclosures to withstand validity challenges.
• Biosimilar Companies: Should anticipate patent challenges early and consider patent workarounds or licensing strategies.
• Litigation Trends: Expect increased focus on patent validity, scope, and procedural defenses under the BPCIA.
• Regulatory Navigation: Synchronize patent and regulatory strategies, especially regarding 351(k) biosimilar approvals.
• Market Impact: Patent disputes influence timing and market entry strategies, potentially delaying biosimilar access.

---

Key Takeaways

• The lawsuit underscores the importance of patent robustness for biologics and biosimilars.
• Both patent validity and infringement are contested issues, requiring precise claim interpretation.
• The case exemplifies legal hurdles biosimilar developers face despite regulatory approval pathways.
• Court decisions will impact the strategic patenting and litigation approaches for biologic firms.
• Stakeholders must navigate complex contrasts between patent law, FDA regulations, and industry practices.

---

Frequently Asked Questions (FAQs)

1. What are the main legal issues in Genentech v. Aurobindo?
   The case primarily revolves around patent infringement and patent validity challenges related to rituximab biosimilars under the BPCIA.

2. How does the BPCIA influence this litigation?
   The BPCIA establishes a framework for biosimilar approval and patent dispute resolution, affecting timing and procedural aspects of patent litigations like this.

3. What are common defenses used by biosimilar companies against patent infringement claims?
   They often challenge patent validity (obviousness, prior art), argue non-infringement, or claim procedural defects (e.g., notice deadlines).

4. What impact could this case have on the biosimilar industry?
   The case may set precedents regarding patent scope, validity, and enforcement, influencing future biosimilar patent strategies and litigation.

5. What are the critical factors in patent validity challenges for biologics?
   Key factors include prior art references, enablement, written description, and the scope of claims relative to existing technologies.

---

Citations

[1] U.S. Patent and Trademark Office (USPTO), Patent Database, 2010-2016.
[2] 42 U.S.C. § 262, Biologics Price Competition and Innovation Act of 2009.
[3] Court filings in Genentech, Inc. v. Aurobindo Pharma Limited, 1:19-cv-00078-RGA, U.S. District Court, District of Delaware.
[4] Industry analyses and legal commentary, see https://biosimilarcompetition.com, accessed 2023.

---

This report provides a comprehensive review of the litigation landscape for Genentech v. Aurobindo, vital for stakeholders involved in biologics development, patent strategy, and biosimilar market entry.